Michael Cherny
Stock Analyst at Leerink Partners
(5.00)
# 10
Out of 4,915 analysts
112
Total ratings
57.14%
Success rate
131.17%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PGNY Progyny | Upgrades: Outperform | $28 | $23.52 | +19.05% | 11 | Jul 8, 2025 | |
| CAH Cardinal Health | Maintains: Buy | $165 → $170 | $155.22 | +9.52% | 12 | Jun 10, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.19 | +152.10% | 2 | May 28, 2025 | |
| MCK McKesson | Maintains: Buy | $755 → $800 | $693.54 | +15.35% | 13 | May 9, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $18.89 | +21.76% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $427.20 | -22.75% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $66.18 | -39.56% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $62.10 | +20.77% | 11 | Feb 13, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $58.75 | +53.19% | 2 | Feb 7, 2025 | |
| ALGN Align Technology | Upgrades: Outperform | $235 → $280 | $129.01 | +117.04% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $135 → $174 | $167.41 | +3.94% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $67.65 | +24.17% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $185.86 | +33.43% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $169.19 | +50.72% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $14.31 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $286.08 | -3.87% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $23 → $22 | $11.64 | +89.00% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $260.08 | -0.03% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $23 | $21.46 | +4.85% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.79 | +67.01% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $9.84 | +93.09% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $7.21 | +135.78% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $6.05 | +767.77% | 2 | Jan 5, 2022 |
Progyny
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $23.52
Upside: +19.05%
Cardinal Health
Jun 10, 2025
Maintains: Buy
Price Target: $165 → $170
Current: $155.22
Upside: +9.52%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.19
Upside: +152.10%
McKesson
May 9, 2025
Maintains: Buy
Price Target: $755 → $800
Current: $693.54
Upside: +15.35%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $18.89
Upside: +21.76%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $427.20
Upside: -22.75%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $66.18
Upside: -39.56%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $62.10
Upside: +20.77%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $58.75
Upside: +53.19%
Align Technology
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $129.01
Upside: +117.04%
Jan 6, 2025
Upgrades: Outperform
Price Target: $135 → $174
Current: $167.41
Upside: +3.94%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $67.65
Upside: +24.17%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $185.86
Upside: +33.43%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $169.19
Upside: +50.72%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $14.31
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $286.08
Upside: -3.87%
Mar 18, 2024
Maintains: Market Perform
Price Target: $23 → $22
Current: $11.64
Upside: +89.00%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $260.08
Upside: -0.03%
Feb 26, 2024
Initiates: Market Perform
Price Target: $23
Current: $21.46
Upside: +4.85%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $4.79
Upside: +67.01%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $9.84
Upside: +93.09%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $7.21
Upside: +135.78%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $6.05
Upside: +767.77%